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Abstract
Background: Soluble CD163 (sCD163) has been associated with arterial inflammation and non-calcified plaques in
human immunodeficiency virus (HIV)-infected individuals and has therefore been suggested as a predictive
biomarker of myocardial infarction (MI).
Methods: We conducted a nested case–control study of 55 cases with first-time MI and 182 controls matched for
age, duration of antiretroviral therapy (ART), gender, smoking, and no known cardiovascular disease. All patients had
four available plasma samples, 1: Before initiation of antiretroviral therapy (ART), 2: Three months after ART, 3: One
year before the case’s MI, and 4: The last sample available before the case’s MI. We used conditional logistic
regression to estimate the association of sCD163 with first-time MI.
Results: The two groups had similar HIV-parameters and cardiovascular risk factors were equally distributed. There
was no significant association between sCD163 and MI neither in samples obtained one year before (OR 1.05, CI
95% 0.85 – 1.29, p = 0.66) nor two months before (OR 1.20, CI 95% 0.98-1.47 p = 0.08).
Conclusion: sCD163 did not prove to be a useful biomarker for prediction of first-time MI in a HIV-infected
population.
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Background
Patients infected with human immunodeficiency virus
(HIV) are at increased risk of myocardial infarction (MI)
[1], but the pathophysiological mechanisms are not fully
understood.
Studies have found not only a higher prevalence of
traditional risk factors for cardiovascular disease (CVD)
[2] but also a high prevalence of asymptomatic athero-
sclerotic lesions among HIV-infected individuals [3].
These lesions are mainly non-calcified and have higher
contents of inflammatory components, which make
them more vulnerable and prone to rupture [4].
Soluble CD163 (sCD163) is a marker of activated
macrophages and is associated with coronary atheroscler-
otic burden in the general population [5] and both arterial
inflammation and non-calcified plaques in HIV-infected
individuals [6,7]. Therefore, we sought to investigate if
sCD163 may serve as a prognostic marker of first-time MI
in an HIV-infected population. We analyzed levels of
sCD163 in plasma from 55 HIV-infected patients with
first-time MI at four time points and compared
them to matched HIV-infected patients without cardiovas-
cular events.* Correspondence: andreas.knudsen@hvh.regionh.dk1Department of Infectious Diseases, Copenhagen University Hospital,
Kettegaard Allé 30, Hvidovre 2650, Denmark
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Methods
We conducted a nested case–control study by extracting
data on patients given a diagnosis of ischaemic heart dis-
ease and HIV (International Classification of Diseases-10th
Revision (ICD-10) I20-25, and HIV, ICD-10 B20-24) from
January 1998 to December 2008. Data were extracted from
the Danish National Hospital Register, which records data
on all patients discharged from a non-psychiatric hospital
in Denmark. We then identified the patients registered
in the Danish HIV Cohort Study (DHCS), which is a na-
tionwide, prospective, population-based cohort study of all
Danish HIV-infected individuals described elsewhere [8].
Among these we identified patients followed at either
Department of Infectious diseases, Rigshospitalet or
Department of Infectious Dieases, Hvidovre Hospital,
Copenhagen, Denmark, which have systematically saved
plasma samples from all quarterly visits by HIV-infected
patients. All patients had given written consent to further
analysis of the blood samples. We then conferred with
patients’ medical records and only patients with verified MI
according to international criteria [9] were included in
the study.
The date of MI served as index date for the selection of
controls, who were already enrolled in the DHCS at the
time of case’s MI. We used an incidence density sampling
and obtained up to 4 controls per case. We excluded cases
Table 1 Demographic, metabolic and HIV characteristics of the patients
Variable Cases Controls p-valuea
Number of patients 55 182
Gender (male/female) (%) 50/5 (91/9) 167/15 (92/8)
Age at time of MI/index date median (IQR), years 49 (42 – 57) 50 (43 – 57)
Duration of HIV before MI/index date median (IQR), years 10 (6 – 17) 10 (7 – 16) 0.71
Mean duration of therapy before MI/index date median (IQR), years 6 (3 – 8) 6 (3 – 9)
Intervals between plasma samples
From sample 1 to initiation ART, median (IQR), days 42 (24 – 76) 49 (32 – 81)
From initiation of ART to sample 2 median (IQR), days 99 (88 – 123) 109 (87 – 142)
From sample 3 to MI/index date median (IQR), days 334 (292 – 367) 368 (334 – 408)
From sample 4 to MI/index date median (IQR), days 52 (27 – 82) 0 (0 – 0)
Smoking (never/ever) (%) 2/53 (4/96) 6/176 (3/97)
Blood pressure, systolic median (IQR) 135 (120 – 149) n = 36 125 (115 – 140) n = 87 0.09
CD4 cell count/mm3, median (IQR)¤ 496 (290–688) n = 52 547 (307–800) n = 161 0.78
HIV-RNA copies/mL, median (range)¤ 39 (19–217200) 39 (19–93900) 0.08
Number of patients with HIV-RNA < 400 copies/mL¤ 44 (80%) 146 (89%) 0.12
Creatinine μM, median (IQR)¤ 81 (70–89) 78 (70–88) 0.38
mg/dL, median (IQR) 1.1 (0.9–1.2) n = 48 1.0 (0.9–1.2) n = 148
Cholesterol mM, median (IQR)¤ 6.3 (5.5–8.0) 5.7 (5.0–6.7) 0.38
mg/dL, median (IQR) 241 (214–309) n = 32 220 (193–255) n = 96
Lipid-lowering treatment (%)# 6 4 0.6
Starting antihypertensive treatment (%)# 13 4 0.07
Starting anti-coagulative treatment (%)# 4 3 0.67
Co-infected with hepatitis B (%) (HbsAg positive) 6 7 0.6
Co-infected with hepatitis C (%) (HCV-Ab-positive) 6 14 0.07
Exposed to ART (%)# 100 100 -
Exposed to NRTI (%)# 100 99.5 0.76
Exposed to abacavir (%)# 56 39 0.007
Exposed to NNRTI (%)# 73 58 0.006
Exposed to PI (%)# 87 84 0.24
a univariate conditional logistic regression.
¤ plasma sample 4 (at time of MI/index date).
# within the study period.
Abbreviations: ART, Antiretroviral therapy; B-glucose, blood-glucose; HIV, Human immunodeficiency virus; MI, Myocardial infarction; NNRTI, Nonnucleoside
reverse-transcriptase inhibitors; NRTI, Nucleoside reverse-transcriptase inhibitors; PI, Protease inhibitors.
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and controls with diabetes and/or prior cardiovascular
disease, other than hypertension. All patients in the study
received antiretroviral therapy (ART).
The study was approved by the scientific ethics com-
mittee of the capital region of Denmark (reference num-
ber H-D-2008-108).
Matching
Controls were matched with their case for age at the time
of MI ± 3 years, gender, duration of ART, and smoking
with a dichotomous status of either smoking (ever) or non-
smoking (never).
Study set-up
The study set-up included 4 time points for each patient
where both plasma samples had been frozen and quar-
terly blood analysis had been performed: Sample 1: last
sample before initiation of ART, Sample 2: three months
after initiation of ART, Sample 3: one year before case’s
MI/index date, and Sample 4: last sample before case’s
MI/index date. Time intervals between the samples are
shown in Table 1.
Risk estimation
An individual risk estimation was calculated based on
blood pressure measurements within the study period
and values of total cholesterol from sample 3 or 4 using
the HeartScore for European high risk countries that
Denmark belonged to at time of cases’ MI. This model
estimates the 10-year risk of fatal CVD [10].
Plasma analysis of CD163
Plasma samples were all stored at −80°C until the analysis
of sCD163, which was determined in duplicate by an in-
house sandwich enzyme-linked immunosorbent assay using
a BEP-2000 ELISA-analyser (Dade Behring, Deerfield, IL,
USA) essentially as previously described [11]. Briefly, rabbit
anti-CD163 (2 mg/L) was coated onto microtitre wells and
plates transferred to a BEP-2000 enzyme-linked immuno-
sorbent assay (ELISA)-analyzer (Dade Behring, Eschborn,
Germany). Samples (diluted 1:101) were added in dupli-
cates and incubated for 1.5 h at 37°C. Monoclonal
anti-CD163 (GHI/61, 3 μg/mL) was added followed by in-
cubation for 1 h at 37°C with horseradish peroxidase-
labelled goat antimouse antibodies (0.125 μg/mL; Dako,
Glostrup, Denmark). The assay was calibrated using serum
traceable to purified human CD163, with the lowest cali-
brator being 6.25 μg/L. The inter-assay coefficient of vari-
ation was 3.0% at 1.33 mg/L and 4.7% at 3.71 mg/L on
control samples included on each plate (28 runs). sCD163
is stable in plasma and withstands repeated freeze-thaw cy-
cles of samples [12].
Statistical analysis
We used conditional logistic regression to estimate odds ra-
tios (OR) and 95% confidence intervals (CI) for the associ-
ation of sCD163 and MI and for comparison between cases
and controls. We adjusted for covariables by performing
multiple conditional regression analysis. sCD163 was used
as a continuous variable.
Levels of sCD163 at different time points within the
groups were compared using a paired t-test on log10-
transformed data. We compared differences in levels of
log10-transformed sCD163 according to treatment regimen
with an independent samples t-test.
The prognostic performance of sCD163 was evaluated
constructing a reciever operating characteristic (ROC)
curve. With a 55 cases and 182 controls the study was
powered at 80% with a 2-sided significance level of 0.05 to
detect an absolute difference of 0.5 mg/L sCD163 based
on previously reported standard deviation. We considered
a p < 0.05 significant. All statistics were performed on SPSS
20 (IBM SPSS Statistics for Windows, Version 20.0.
Armonk, NY: IBM Corp.).
Results
We identified 55 cases and 182 controls. Twenty seven
cases had 4 controls, 20 cases had 3 controls, 6 cases had 2
and 2 cases had 1 control. Patient characteristics are shown
in Table 1.
Both cases and controls were predominantly white
(93 and 94% respectively). Modes of infection were similar
between the groups with 69 and 67% homosexually
infected, 18 and 22% heterosexually infected, and 4 and 6%
infected by intravenous drug abuse respectively. The
10-year risk of fatal CVD was calculated in the 99 subjects
who had all the necessary parameters (29 cases and 70 con-
trols) and there was no significant difference between the
two groups (3.3 in the control group and 5.3 among cases,
p = 0.20).
More than 80% of the patients in both groups had
suppressed viral load (< 400 copies/mL) and CD4 cell
counts above 400 cells/μL in plasma sample 4, and meta-
bolic cardiovascular risk factors were equally distributed in
cases and controls. A total of 32 cases had ST-elevation MI
(STEMI), 16 cases had Non-ST-elevation MI (NSTEMI)
and 7 cases had non-specified MI.
The initiation of ART resulted in a significant increase
in CD4 cell counts and a significant decrease in HIV
RNA levels in both groups. The suppression of viral load
was maintained equally in both groups, and CD4 cells
continued to rise in the following samples.
Figure 1 shows that both groups decreased in plasma
levels of sCD163 3 months after initiation of ART although
only the control group reached significance. The plasma
levels continued to decrease during ART reaching steady
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levels 1 year prior to the case’s MI. The cases showed no
statistically significant rise in sCD163 plasma levels prior to
their MI.
The two groups did not differ in plasma levels of sCD163
in any of the 4 consecutive samples, but the association be-
tween sCD163 and MI grew stronger in sample 4 (OR 1.2,
CI 0.98-1.47, p = 0.08), Table 2.
In a multiple conditional regression model adjusting for
HIV RNA sCD163 remained non significant (OR 1.20, CI
0.96 – 1.51, p = 0.11) To evaluate the possible role of
sCD163 in sample 4 as a predictor of MI we constructed a
ROC curve for sCD163 which gave an area under the curve
of 0.57 (CI 95% 0.48-0.65 p = 0.14), Figure 2.
All patients in the study received ART and had all been
exposed to nucleosid reverse transcriptase inhibitors
(NRTIs) and both groups had been equally exposed to pro-
tease inhibitors (PIs) (p = 0.24). A significantly larger num-
ber of cases had been exposed to NNRTIs (p = 0.006) and
the NRTI, abacavir (p = 0.007). In a multiple conditional
regression model adjusting for exposure to abacavir,
NNRTI, and PI sCD163 remained non significant (OR 1.14,
CI 0.92 – 1.40, p = 0.22).
No difference in plasma levels of sCD163 was found
between cases exposed (n = 31) and not exposed (n = 24)
to abacavir in plasma sample 3 or 4 (p = 0.71 and 0.20
respectively).
Discussion
In this case–control study of 237 HIV-infected patients
with similar cardiovascular risk factors and comparable risk
estimations we did not find that sCD163 could serve as
predictive biomarker of first-time MI. Macrophages are key
players in the development of atherosclerosis [13] and their
possible mechanistic role behind the increased risk in the
HIV-infected population is currently subject to attention
[14]. Studies in HIV-infected patients have recently associ-
ated markers of activated macrophages with arterial inflam-
mation [7], increased progression of carotid intima-media
thickness [15], and noncalcified plaques [6] suggesting that
these markers may serve as predictors of clinical events.
Despite these promising results, our study did not sup-
port the use of sCD163 as a predictive marker of first-time
MI in an HIV-infected population neither one year before
MI nor approximately 2 months before MI as underlined
by the ROC-curve in Figure 2.
A recent study found an association between HIV-RNA
levels >50 copies/mL and MI in patients infected with HIV
[16], and HIV-infection has, primarily through HIV-RNA
viral load, been shown to increase markers of endothelial
dysfunction [17]. We therefore performed an analysis of the
Figure 1 Mean plasma levels of sCD163 (mg/L) at 1:last sample
before initiation of ART, 2: three months after ART, 3: one year
before case’s MI/index date, and 4: last sample before case’s
MI/index date. Bars represent standard error of the mean (SEM).
* Indicates a significant decrease in plasma level of sCD163 from the
previous time point (p < 0.05).
Table 2 Median plasma levels of sCD163 in mg/L (IQR) at
1: last sample before initiation of ART, 2: three months
after ART, 3: one year before case’s MI/index date, and 4:
last sample before case’s MI/index date
Sample 1 Sample 2 Sample 3 Sample 4
Cases 3.22 2.87 2.33 2.38
(2.53 – 4.32) (2.22 – 3.51) (1.73 – 3.31) (1.86 – 3.58)
n = 51 n = 49 n = 51 n = 55
Controls 3.03 2.68 2.24 2.24
(2.50 – 4.58) (2.13 – 3.70) (1.65 – 2.98) (1.69 – 2.99)
n = 165 n = 161 n = 172 n = 176
p – valuesa 0.67 0.48 0.66 0.08














Figure 2 Receiver-operator characteristics (ROC) curve for
plasma sCD163 at sample 4 for the occurrence of MI. Area
under the curve (AUC) for sCD163 is 0.57 (CI 95% 0.48-0.65 p = 0.14).
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association of sCD163 and MI adjusting for viral load
which remained non-significant.
The association between abacavir and MI has been thor-
oughly examined in the recent years with different conclu-
sions [18]. Data from the SMART-study and D:A:D-study
group suggested that abacavir had proinflammatory proper-
ties causing elevated levels of high sensitivity C-reactive
protein and interleukin 6, and that the increased risk of MI
therefore could relay on vascular inflammation [19]. In a
study with positron emission tomography sCD163 has re-
cently been associated with vascular inflammation [7], but
our model adjusting for antiretroviral treatment did not,
however, suggest that abacavir influenced the levels of
sCD163 and levels of sCD163 were not significantly higher
in cases treated with abacavir. This suggests a different
mechanism of action other than activation of macrophages
if abacavir is contributing to the risk of MI.
To the best of our knowledge this study is the first to
evaluate the association of sCD163 and MI in a population
infected with HIV. This nested case–control setup pro-
vides unique possibility to assess the association between
sCD163 and hard end-point cardiovascular disease in a
cohort of well controlled and closely followed patients
infected with HIV who had blood samples analysed quar-
terly at university centres. We matched our patients for
factors known to influence the risk of MI thus focusing
on sCD163.
On the other hand, case–control studies do offer cer-
tain challenges in form of e.g. selection bias, which we
tried to account for since all cases were possible controls
until their MI. The cases were selected from a period of
ten years and laboratory techniques may have changed
over time and some analyses were not available during
the first years. Some samples had been frozen for several
years before the measurement of sCD163, which may
have led to some degradation of the protein, although
this has been proven very stable [12].
The SCORE risk estimation only gives estimates within
the age 40 to 65 and some of our patients were younger
than this; further, a substantial proportion of the patients
could not have a SCORE risk estimated due to missing
values of cholesterol and systolic blood pressure. This may
conceale an underlying difference between the two groups.
The stratification of smoking status into smoking
(ever) or non-smoking (never) carries no information on
the amount of smoking exposure and causes a less cer-
tain matching. With > 95% of the patients in the smok-
ing (ever) stratum the ability of extrapolating data to a
non-smoking population is impeded.
Finally, the number of cases in our study was rela-
tively low, and with a power of 80% to detect a differ-
ence of 0.5 mg/L sCD163, we cannot exclude the
possibility of a statistical type II error overlooking sig-
nificant changes.
Conclusions
In this nested case-control study we did not find sCD163 to
be a useful biomarker for prediction of first-time MI in a
HIV-infected population.
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